147 related articles for article (PubMed ID: 26044169)
1. Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement.
Tsitoura D; Ambery C; Price M; Powley W; Garthside S; Biggadike K; Quint D
Clin Pharmacol Ther; 2015 Oct; 98(4):369-80. PubMed ID: 26044169
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial.
Ellis AK; Tsitoura DC; Quint D; Powley W; Lee LA
Clin Exp Allergy; 2017 Sep; 47(9):1193-1203. PubMed ID: 28681506
[TBL] [Abstract][Full Text] [Related]
3. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
Siddall H; Quint D; Pandya H; Powley W; Shabbir S; Hohlfeld JM; Singh D; Lee L
PLoS One; 2020; 15(11):e0240964. PubMed ID: 33166307
[TBL] [Abstract][Full Text] [Related]
4. GSK2245035, a TLR7 agonist, Does Not Increase Pregnancy Loss in Cynomolgus Monkeys.
Posobiec LM; Hillegas AE; Baker A; Phadnis-Moghe AS; Maier CC; Stanislaus DJ; Bray M; Price MA
J Reprod Immunol; 2021 Feb; 143():103242. PubMed ID: 33212303
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8H-purin-8-one (GSK2245035), a Highly Potent and Selective Intranasal Toll-Like Receptor 7 Agonist for the Treatment of Asthma.
Biggadike K; Ahmed M; Ball DI; Coe DM; Dalmas Wilk DA; Edwards CD; Gibbon BH; Hardy CJ; Hermitage SA; Hessey JO; Hillegas AE; Hughes SC; Lazarides L; Lewell XQ; Lucas A; Mallett DN; Price MA; Priest FM; Quint DJ; Shah P; Sitaram A; Smith SA; Stocker R; Trivedi NA; Tsitoura DC; Weller V
J Med Chem; 2016 Mar; 59(5):1711-26. PubMed ID: 26861551
[TBL] [Abstract][Full Text] [Related]
6. Cytological assessment of the epithelial cells of the nasal mucous membrane after local fluticasone therapy.
Trybus E; Krol T; Obarzanowski T; Trybus W; Kopacz-Bednarska A; Obarzanowski M
J Physiol Pharmacol; 2015 Feb; 66(1):139-47. PubMed ID: 25716973
[TBL] [Abstract][Full Text] [Related]
7. Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber.
Murdoch RD; Bareille P; Ignar D; Mark S; Miller SR; Gupta A; Salapatek AM; Patel P
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):811-8. PubMed ID: 26249767
[TBL] [Abstract][Full Text] [Related]
8. Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis.
Jha A; Thwaites RS; Tunstall T; Kon OM; Shattock RJ; Hansel TT; Openshaw PJM
J Allergy Clin Immunol; 2021 Feb; 147(2):694-703.e12. PubMed ID: 32717253
[TBL] [Abstract][Full Text] [Related]
9. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis.
Greiff L; Cervin A; Ahlström-Emanuelsson C; Almqvist G; Andersson M; Dolata J; Eriksson L; Högestätt E; Källén A; Norlén P; Sjölin IL; Widegren H
Respir Res; 2012 Jun; 13(1):53. PubMed ID: 22726593
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis.
Sastre J; Mullol J; Valero A; Valiente R;
Curr Med Res Opin; 2012 Jan; 28(1):121-30. PubMed ID: 22077106
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.
Rosenblut A; Bardin PG; Muller B; Faris MA; Wu WW; Caldwell MF; Fokkens WJ
Allergy; 2007 Sep; 62(9):1071-7. PubMed ID: 17686110
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma.
Xirakia C; Koltsida O; Stavropoulos A; Thanassopoulou A; Aidinis V; Sideras P; Andreakos E
Am J Respir Crit Care Med; 2010 Jun; 181(11):1207-16. PubMed ID: 20224068
[TBL] [Abstract][Full Text] [Related]
13. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment.
Meltzer EO; Berkowitz RB; Grossbard EB
J Allergy Clin Immunol; 2005 Apr; 115(4):791-6. PubMed ID: 15806000
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen.
Jacobs R; Martin B; Hampel F; Toler W; Ellsworth A; Philpot E
Curr Med Res Opin; 2009 Jun; 25(6):1393-401. PubMed ID: 19419338
[TBL] [Abstract][Full Text] [Related]
15. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study.
Rimmer J; Peake HL; Santos CM; Lean M; Bardin P; Robson R; Haumann B; Loehrer F; Handel ML
Clin Exp Allergy; 2007 Jan; 37(1):8-14. PubMed ID: 17210036
[TBL] [Abstract][Full Text] [Related]
16. Effects of intranasal mometasone furoate on itchy ear and palate in patients with seasonal allergic rhinitis.
Bernstein DI; Teper A; Gopalan G; Gates D
Ann Allergy Asthma Immunol; 2012 May; 108(5):359-62. PubMed ID: 22541408
[TBL] [Abstract][Full Text] [Related]
17. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.
Shah SR; Nayak A; Ratner P; Roland P; Michael Wall G
Clin Ther; 2009 Jan; 31(1):99-107. PubMed ID: 19243710
[TBL] [Abstract][Full Text] [Related]
18. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis.
Patel P; Patel D; Kunjibettu S; Hall N; Wingertzahn MA
Ear Nose Throat J; 2008 Jun; 87(6):340-53. PubMed ID: 18561117
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of azelastine and levocabastine nasal sprays in patients with seasonal allergic rhinitis.
Falser N; Wober W; Rahlfs VW; Baehre M
Arzneimittelforschung; 2001; 51(5):387-93. PubMed ID: 11413739
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis.
Ratner P; Van Bavel J; Mohar D; Jacobs RL; Hampel F; Howland W; Karwal R
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):141-7. PubMed ID: 25624132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
